Real-world impact of rotavirus vaccination.

  title={Real-world impact of rotavirus vaccination.},
  author={Manish M Patel and Duncan A. Steele and Jon R. Gentsch and John Wecker and Roger I Glass and Umesh D. Parashar},
  journal={The Pediatric infectious disease journal},
  volume={30 1 Suppl},
Summary of Studies in the Current Supplement That Assess Health Impact, Indirect Benefits, or StrainChanges After Rotavirus Vaccination Location (Ref) Vaccine Key Findings InterpretationHealth impactEl Salvador(15)RV1 35%–48% decline in all cause diarrhea events(outpatient and inpatient) and 69%–81%decline in rotavirus hospitalizations amongchildren 5 yearsThe consistency of the findings across regions, predominantlyduring seasons when rotavirus predominates, withincreasing effect among… 

Baseline Burden of Rotavirus Disease in Sudan to Monitor the Impact of Vaccination

The high burden of rotavirus disease in Sudan indicates that the recently implemented vaccination program should substantially improve child health in Sudan and will be an important platform for assessing the benefits and value of rotvirus vaccine in a developing country setting.

Effect of childhood rotavirus vaccinationon community rotavirus prevalence in rural Ecuador, 2008-13.

Rotarix vaccination was highly effective among children in a rural community setting and provides population-level benefits through indirect protection among adults and may suppress transmission, including asymptomatic transmission, in low- and middle-income settings.

[Impact assessment of the rotavirus vaccine in Colombia using rapid evaluation methods].

In Colombia, rotavirus vaccination protects against hospitalization for diarrhea due to any cause and the use of cross-sectional surveys appeared to be adequate for rapid evaluation of an immunization program's effectiveness with a new vaccine.

Impact of rotavirus vaccines on rotavirus disease

A significant decline in acute gastroenteritis-related deaths among Latin American children was observed after the introduction of RV1 and RV5 vaccines, and postlicensure safety studies assessed rare adverse events, such as intussusception.

Sustained Reduction of Childhood Diarrhea-Related Mortality and Hospitalizations in Mexico After Rotavirus Vaccine Universalization.

A substantial and sustained decline in diarrhea-related hospitalizations and deaths in Mexican children associated with implementation of rotavirus vaccination is documented, highlighting the public health benefits that could result in countries that adopt rotav virus vaccination into their national immunization programs.

Temporal Changes in Pediatric Gastroenteritis after Rotavirus Vaccination in Quebec

Norovirus infections were more prevalent than rotavirus infections among pediatric gastroenteritis cases hospitalized or seeking emergency care, andRotavirus cases were, on average, more clinically severe than norovirus cases among participants of the same age.

Impact of Rotavirus Vaccination in Severe Rotavirus Gastroenteritis Outpatient Visits at Three Pediatric Primary Care Clinics in Shibata City, Niigata Prefecture, Japan

The results suggest that the RV vaccination is effective for the prevention of severe RVGE in Japanese voluntary RV vaccination settings with estimated coverage rates of 32.5%, 40.5% and 47.1% for 2012, 2013 and 2014, respectively.

Effectiveness of live attenuated monovalent human rotavirus vaccination in rural Ecuador, 2008-2013

It is shown that Rotarix vaccination suppresses overall transmission among children in a rural community setting and provides population-level benefits through indirect protection among adults.



Decline in Rotavirus Hospitalizations and Health Care Visits for Childhood Diarrhea Following Rotavirus Vaccination in El Salvador

Rotavirus vaccination had a substantial public health impact on rotav virus disease and overall diarrhea events in El Salvador and important age-related changes in diarrheal incidence emphasize the need for ongoing rotavirus surveillance after vaccine introduction.

Global mortality associated with rotavirus disease among children in 2004.

The high mortality associated with rotavirus disease underscores the need for targeted interventions, such as vaccines, to realize the full life-saving potential of vaccines.

Uptake, Impact, and Effectiveness of Rotavirus Vaccination in the United States: Review of the First 3 Years of Postlicensure Data

The implementation of routine childhood immunization againstRotavirus has rapidly and dramatically reduced the large health burden of rotavirus gastroenteritis in US children and continued monitoring of rotvirus diarrhea is needed to determine if immunity wanes as vaccinated children get older and to better quantify the indirect benefits of vaccination.

Reduction of Diarrhea-associated Hospitalizations Among Children Aged <5 Years in Panama Following the Introduction of Rotavirus Vaccine

RV1 appears to have had a substantial impact on diarrhea-associated hospitalizations among young children in Panama, with reductions similar among infants and those aged 1–4 years of age, even though only 25% of the latter group was likely to have received vaccine by early 2008.

Assessing the effectiveness and public health impact of rotavirus vaccines after introduction in immunization programs.

Data is reviewed for the protective efficacy of the 2 new rotavirus vaccines, with emphasis on issues particularly important for consideration as these vaccines are introduced in routine infant immunization programs.

Impact of Rotavirus Vaccination on Diarrhea-related Hospitalizations Among Children <5 Years of Age in Mexico

Marked declines in diarrhea-related hospitalizations among vaccine-eligible Mexican children <24 months of age have occurred during the first 2 complete rotvirus seasons following rotavirus vaccination, andRotavirus-specific surveillance and epidemiologic studies are necessary for a better understanding of the changes in disease epidemiology and public health impact from rotav virus vaccination.

Pentavalent Rotavirus Vaccine and Prevention of Gastroenteritis Hospitalizations in Australia

RV5 is highly effective at preventing rotavirus hospitalizations in a developed country setting, confirming efficacy figures from the pivotal clinical trial.

Performance of rotavirus vaccines in developed and developing countries

Previous candidate rotavirus vaccines and vaccines in current use are reviewed, with emphasis on their performance in developed versus developing countries, and future efforts for these vaccines should focus on optimizing the efficacy and delivery.

Rotavirus Vaccines in Belgium: Policy and Impact

A decrease in the number of rotavirus infections and a 4- to 6-week delay in the onset of disease and the peak of incidence in the postvaccination period coincides with the increased vaccine uptake.